Skip to main content

Table 3 PSA bounce in each group

From: Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer

 

Hormone naive

Neo-adjuvant ADT

monotherapy

Combined EBRT

monotherapy

Combined EBRT

(n=103)

(n=38)

(n=34)

(n=17)

PSA elevation rate of 0.1 ng/mL or greater

51 (50%)

25 (66%)

9 (27%)

6 (35%)

Frequency of PSA bounce

29 (28%)

12 (32%)

3 (18%)

15 (18%)

Time to bounce (mos)

17.4, 17, (5-36)

14.8, 11.5 (5-35)

13.7, 8.5, (5-26)

18.3, 15, (14-26)

Mean, median, (range)

Height (ng/mL)

0.51, 0.34, (0.13-1.74)

0.48, 0.26, (0.12-1.85)

0.19, 0.16, (0.10-0.40)

0.90, 0.68, (0.16-1.87)

Mean, median, (range)

Duration (mos)

9.1, 6.0, (3-36)

11.8, 11.5, (2-31)

6.0, 6.0, (3-9)

15.3, 17.0, (7-22)

Mean, median, (range)

3-yr bounce free rate (%)

68.8

80.6

66.7

80.9